BioInvent's Tie-Up With Cancer Research Technology Brings Some Relief From Pipeline Setbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
Sweden's BioInvent forges links with researchers at Queen Mary, University of London, and Cancer Research Technology, the commercial arm of charity Cancer Research UK, to identify new therapeutic antibodies for oncology.
You may also be interested in...
BioInvent To Cut Jobs By A Quarter Following Head-To-Head Clinical Trial Disappointment
Sweden's antibody platform company BioInvent moves quickly to reorganize following disappointing Phase IIb clinical results with a potential antithrombotic antibody.
Roche To Partner With Two European Biotechs On Oncology Candidate
Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.